Heidelberg Pharma AG Stock
Heidelberg Pharma AG Stock
The Heidelberg Pharma AG stock is trending slightly upwards today, with an increase of €0.010 (0.370%) compared to yesterday's price.
So far the community has only identified positive things for Heidelberg Pharma AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 0.370% | -3.546% | -9.934% | 2.256% | 12.863% | -37.471% | -65.306% |
| Vivoryon Therapeutics N.V. | -1.820% | 4.580% | 0.146% | -23.206% | -5.256% | -90.539% | -90.565% |
| Nanorepro AG | 2.830% | 2.166% | -6.908% | -0.702% | -5.980% | -34.793% | -89.393% |
| Northwest Biotherapeutics Inc. | 0.000% | -11.111% | -12.088% | -15.789% | -22.330% | -69.231% | -85.965% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
EQS-News: Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
EQS-News: Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026